Trial Profile
A Phase I/IIa Open-label First-in-Human Study to Assess Safety and Pharmacokinetics and Explore Biomarker Effects of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Subjects With Cutaneous Warts
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Digoxin/furosemide (Primary)
- Indications Warts
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Cutanea Life Sciences
- 22 May 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 16 Apr 2014 New trial record